Von Willebrand Factor Propeptide: A Potential Disease Biomarker Not Affected by ABO Blood Groups

Overview

Journal Biomark Insights

Publisher Sage Publications

Date 2015 Sep 5

PMID 26339184

Citations 3

Authors

Mahat Marianor

Abdullah Wan Zaidah

Ch Che Maraina

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies have shown that vascular-related disorders are associated with high von Willebrand factor antigen (VWF:Ag) and VWF propeptide (VWFpp). VWFpp is secreted together with VWF:Ag upon endothelial cell activation, hence it could be a potential biomarker. This study was conducted to compare between VWF:Ag and VWFpp levels among 30 healthy individuals and 42 patients with high levels of VWF:Ag in different medical conditions and ABO blood groups. VWFpp levels were strongly correlated with VWF:Ag. VWF:Ag and VWFpp levels were significantly increased in patients compared to healthy individuals. VWFpp is not affected by ABO blood group in both healthy individual and patient groups unlike VWF:Ag. As expected, this study showed that VWFpp levels increased in parallel with VWF:Ag levels in patients with diseases associated with endothelial activation. VWFpp though nonspecific is a potential biomarker reflecting underlying pathophysiological changes in various medical conditions with an additional advantage of not being influenced by ABO blood groups.

Citing Articles

Plasma VWF: Ag levels predict long-term clinical outcomes in patients with acute myocardial infarction.

Xier Z, Zhu Y, Tang S, Kong C, Aili D, Huojia G Front Cardiovasc Med. 2023; 9:1013815.

PMID: 36684571 PMC: 9845945. DOI: 10.3389/fcvm.2022.1013815.

Elevated Plasma von Willebrand Factor Antigen and Activity Levels Are Associated With the Severity of Coronary Stenosis.

Yan B, Wang Q, Du W, Zhai S, Gou C, Hu T Clin Appl Thromb Hemost. 2020; 26:1076029619900552.

PMID: 31964151 PMC: 7098204. DOI: 10.1177/1076029619900552.

Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Ozel A, McGee B, Siemieniak D, Jacobi P, Haberichter S, Brody L J Thromb Haemost. 2016; 14(9):1888-98.

PMID: 27359253 PMC: 5035595. DOI: 10.1111/jth.13401.

References

Nossent A, van Marion V, VAN Tilburg N, Rosendaal F, Bertina R, van Mourik J . von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost. 2006; 4(12):2556-62. DOI: 10.1111/j.1538-7836.2006.02273.x. View

Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, Ohishi K . Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res. 2011; 129(5):598-602. DOI: 10.1016/j.thromres.2011.10.011. View

Casonato A, Gallinaro L, Cattini M, Pontara E, Padrini R, Bertomoro A . Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica. 2010; 95(8):1366-72. PMC: 2913086. DOI: 10.3324/haematol.2009.019927. View

Hyseni A, Roest M, Braun S, Barendrecht A, de Groot P, Ndrepepa G . Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. Thromb Res. 2013; 131(3):198-203. DOI: 10.1016/j.thromres.2012.12.001. View

Franchini M, Lippi G . Von Willebrand factor and thrombosis. Ann Hematol. 2006; 85(7):415-23. DOI: 10.1007/s00277-006-0085-5. View

Eikenboom J, Federici A, Dirven R, Castaman G, Rodeghiero F, Budde U . VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013; 121(12):2336-9. PMC: 4191434. DOI: 10.1182/blood-2012-09-455089. View

Stufano F, La Marca S, Pontiggia S, Musallam K, Peyvandi F . von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012; 10(4):728-30. DOI: 10.1111/j.1538-7836.2012.04642.x. View

Peyvandi F, Garagiola I, Baronciani L . Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011; 9 Suppl 2:s3-8. PMC: 3159913. DOI: 10.2450/2011.002S. View

Sztukowska M, Gallinaro L, Cattini M, Pontara E, Sartorello F, Daidone V . Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol. 2008; 143(1):107-14. DOI: 10.1111/j.1365-2141.2008.07311.x. View

10.

Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schofl R . Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013; 39(3):331-8. DOI: 10.1111/apt.12564. View

11.

Chan Y . Biostatistics 104: correlational analysis. Singapore Med J. 2004; 44(12):614-9. View

12.

Morange P, Simon C, Alessi M, Luc G, Arveiler D, Ferrieres J . Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004; 109(11):1343-8. DOI: 10.1161/01.CIR.0000120705.55512.EC. View

13.

Lopes A, Barreto A, Maeda N, Cicero C, Soares R, Bydlowski S . Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. Braz J Med Biol Res. 2011; 44(12):1269-75. DOI: 10.1590/s0100-879x2011007500149. View

14.

Wennberg P, Wensley F, Di Angelantonio E, Johansson L, Boman K, Rumley A . Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res. 2011; 129(1):68-73. DOI: 10.1016/j.thromres.2011.05.015. View

15.

Van Schie M, De Maat M, Dippel D, de Groot P, Lenting P, Leebeek F . von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost. 2010; 8(6):1424-6. DOI: 10.1111/j.1538-7836.2010.03863.x. View

16.

Gallinaro L, Cattini M, Sztukowska M, Padrini R, Sartorello F, Pontara E . A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111(7):3540-5. DOI: 10.1182/blood-2007-11-122945. View

17.

Sonneveld M, de Maat M, Leebeek F . Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014; 28(4):167-78. DOI: 10.1016/j.blre.2014.04.003. View

18.

Verrotti A, Greco R, Basciani F, Morgese G, Chiarelli F . von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res. 2003; 53(3):382-6. DOI: 10.1203/01.PDR.0000049509.65496.BF. View

19.

Haberichter S, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo D . Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006; 108(10):3344-51. PMC: 1895439. DOI: 10.1182/blood-2006-04-015065. View

20.

Reininger A . VWF attributes--impact on thrombus formation. Thromb Res. 2008; 122 Suppl 4:S9-13. DOI: 10.1016/S0049-3848(08)70028-8. View